See more : Geely Automobile Holdings Limited (0175.HK) Income Statement Analysis – Financial Results
Complete financial analysis of OrbusNeich Medical Group Holdings Limited (6929.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OrbusNeich Medical Group Holdings Limited, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Simplex Infrastructures Limited (SIMPLEXINF.BO) Income Statement Analysis – Financial Results
- Lufax Holding Ltd (LU) Income Statement Analysis – Financial Results
- Mahube Infrastructure Limited (MHB.JO) Income Statement Analysis – Financial Results
- Universal Robina Corporation (UVRBF) Income Statement Analysis – Financial Results
- SHREE HANUMAN SUGAR & INDUSTRI (HANSUGAR.BO) Income Statement Analysis – Financial Results
OrbusNeich Medical Group Holdings Limited (6929.HK)
About OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company was founded in 2001 and is headquartered in Shatin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 153.87M | 136.82M | 116.46M | 88.47M | 96.34M |
| Cost of Revenue | 47.37M | 44.37M | 35.29M | 30.45M | 30.90M |
| Gross Profit | 106.50M | 92.46M | 81.17M | 58.02M | 65.45M |
| Gross Profit Ratio | 69.22% | 67.57% | 69.70% | 65.58% | 67.93% |
| Research & Development | 14.81M | 14.11M | 12.15M | 12.58M | 9.59M |
| General & Administrative | 18.91M | 22.57M | 19.96M | 14.30M | 15.41M |
| Selling & Marketing | 35.93M | 32.56M | 30.10M | 26.69M | 32.25M |
| SG&A | 54.84M | 55.13M | 50.06M | 40.99M | 49.48M |
| Other Expenses | -3.09M | 9.00K | -14.94M | -43.00K | 0.00 |
| Operating Expenses | 66.56M | 68.33M | 60.82M | 51.16M | 57.46M |
| Cost & Expenses | 113.93M | 112.69M | 96.11M | 81.61M | 88.36M |
| Interest Income | 10.67M | 2.39M | 12.00K | 12.00K | 480.00K |
| Interest Expense | 142.00K | 1.46M | 5.61M | 1.40M | 501.00K |
| Depreciation & Amortization | 4.21M | 3.88M | 4.02M | 4.09M | 2.39M |
| EBITDA | 53.97M | 27.14M | 8.31M | 12.75M | 10.04M |
| EBITDA Ratio | 35.07% | 21.37% | 7.15% | 13.43% | 10.42% |
| Operating Income | 39.94M | 21.07M | 19.44M | 8.69M | 7.65M |
| Operating Income Ratio | 25.96% | 15.40% | 16.69% | 9.83% | 7.94% |
| Total Other Income/Expenses | 9.69M | 719.00K | -20.76M | -1.44M | -482.00K |
| Income Before Tax | 49.63M | 21.79M | -1.32M | 7.26M | 7.51M |
| Income Before Tax Ratio | 32.25% | 15.93% | -1.13% | 8.20% | 7.79% |
| Income Tax Expense | 4.56M | 3.30M | 3.13M | 184.00K | 549.00K |
| Net Income | 45.07M | 18.49M | -4.44M | 7.07M | 6.96M |
| Net Income Ratio | 29.29% | 13.51% | -3.82% | 7.99% | 7.22% |
| EPS | 0.05 | 0.03 | -0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.05 | 0.03 | -0.01 | 0.01 | 0.01 |
| Weighted Avg Shares Out | 833.16M | 724.09M | 576.92M | 576.94M | 579.83M |
| Weighted Avg Shares Out (Dil) | 832.96M | 776.39M | 576.90M | 576.90M | 576.90M |
Source: https://incomestatements.info
Category: Stock Reports